{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Duan LJ"],"funding":["Natural Science Foundation of Beijing Municipality","National Natural Science Foundation of China"],"pagination":["111284"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9371981"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(9)"],"pubmed_abstract":["Preexisting immunity cross-reactive to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in SARS-CoV-1 survivors suggests that a coronavirus disease 2019 vaccine may boost such preexisting cross-reactive memory T cells. We measure SARS-CoV-2 and SARS-CoV-1 spike-specific neutralizing antibody and T cell responses in a single dose of Ad5-nCoV-immunized SARS-CoV-1 survivors 6 months after vaccination. Compared with Ad5-nCoV-immunized naive healthy individuals (NHIs), vaccination of Ad5-nCoV in SARS-CoV-1 survivors boosts the antibody response against SARS-CoV-1 but induces a limited neutralizing antibody that is capable of neutralizing SARS-CoV-2 variants of concern, and nearly all serum samples lose neutralization to Omicron subvariants. Immunized SARS-CoV-1 survivors produce a T cell response to SARS-CoV-2 comparable with that of Ad5-nCoV-immunized NHIs. However, a robust cross-reactive T cell response to SARS-CoV-1 is identified in immunized SARS-CoV-1 survivors compared with Ad5-nCoV-immunized NHIs. These findings suggest that vaccination with Ad5-nCoV elicits a stronger neutralizing antibody and cross-reactive T cell responses against SARS-CoV-1 in SARS-CoV-1 survivors."],"journal":["Cell reports"],"pubmed_title":["SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors."],"pmcid":["PMC9371981"],"funding_grant_id":["92169207","81773494","81621005","L202038"],"pubmed_authors":["Yao L","Ma MJ","Wang GL","Cao WC","Duan LJ","Zhu KL","Cui XM"],"additional_accession":[]},"is_claimable":false,"name":"SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors.","description":"Preexisting immunity cross-reactive to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in SARS-CoV-1 survivors suggests that a coronavirus disease 2019 vaccine may boost such preexisting cross-reactive memory T cells. We measure SARS-CoV-2 and SARS-CoV-1 spike-specific neutralizing antibody and T cell responses in a single dose of Ad5-nCoV-immunized SARS-CoV-1 survivors 6 months after vaccination. Compared with Ad5-nCoV-immunized naive healthy individuals (NHIs), vaccination of Ad5-nCoV in SARS-CoV-1 survivors boosts the antibody response against SARS-CoV-1 but induces a limited neutralizing antibody that is capable of neutralizing SARS-CoV-2 variants of concern, and nearly all serum samples lose neutralization to Omicron subvariants. Immunized SARS-CoV-1 survivors produce a T cell response to SARS-CoV-2 comparable with that of Ad5-nCoV-immunized NHIs. However, a robust cross-reactive T cell response to SARS-CoV-1 is identified in immunized SARS-CoV-1 survivors compared with Ad5-nCoV-immunized NHIs. These findings suggest that vaccination with Ad5-nCoV elicits a stronger neutralizing antibody and cross-reactive T cell responses against SARS-CoV-1 in SARS-CoV-1 survivors.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-18T12:18:55.466Z","creation":"2025-04-06T21:49:22.614Z"},"accession":"S-EPMC9371981","cross_references":{"pubmed":["35987196"],"doi":["10.1016/j.celrep.2022.111284"]}}